{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:12Z","timestamp":1791928932515,"version":"4.3.4"},"reference-count":200,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40263-024-01155-3","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:57:34Z","timestamp":1737727054000},"page":"263-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Targeting Kv7 Potassium Channels for Epilepsy"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-223X","authenticated-orcid":false,"given":"Emilio","family":"Perucca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-0560","authenticated-orcid":false,"given":"Maurizio","family":"Taglialatela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"4","key":"1155_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","volume":"46","author":"RS Fisher","year":"2005","unstructured":"Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, Engel J Jr. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470\u20132. https:\/\/doi.org\/10.1111\/j.0013-9580.2005.66104.x.","journal-title":"Epilepsia"},{"key":"1155_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eplepsyres.2018.04.005","volume":"143","author":"M De Curtis","year":"2018","unstructured":"De Curtis M, Uva L, Gnatkovsky V, Librizzi L. Potassium dynamics and seizures: why is potassium ictogenic? Epilepsy Res. 2018;143:50\u20139. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.04.005.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1155_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/0014-4886(70)90150-0","volume":"26","author":"AP Fertziger","year":"1970","unstructured":"Fertziger AP, Ranck JB Jr. Potassium accumulation in interstitial space during epileptiform seizures. Exp Neurol. 1970;26(3):571\u201385. https:\/\/doi.org\/10.1016\/0014-4886(70)90150-0.","journal-title":"Exp Neurol"},{"key":"1155_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.neubiorev.2017.03.002","volume":"77","author":"A Bellot-Saez","year":"2017","unstructured":"Bellot-Saez A, K\u00e9kesi O, Morley JW, Buskila Y. Astrocytic modulation of neuronal excitability through K+ spatial buffering. Neurosci Biobehav Rev. 2017;77:87\u201397. https:\/\/doi.org\/10.1016\/j.neubiorev.2017.03.002.","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"1155_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1212\/01.wnl.0000343739.72081.4e","volume":"72","author":"EE Benarroch","year":"2009","unstructured":"Benarroch EE. Potassium channels: brief overview and implications in epilepsy. Neurology. 2009;72(7):664\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000343739.72081.4e.","journal-title":"Neurology"},{"issue":"Pt 11","key":"1155_CR6","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1113\/jphysiol.2010.188417","volume":"588","author":"VC Wimmer","year":"2010","unstructured":"Wimmer VC, Reid CA, So EY, Berkovic SF, Petrou S. Axon initial segment dysfunction in epilepsy. J Physiol. 2010;588(Pt 11):1829\u201340. https:\/\/doi.org\/10.1113\/jphysiol.2010.188417.","journal-title":"J Physiol"},{"issue":"6","key":"1155_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/ane.13695","volume":"146","author":"K Gao","year":"2022","unstructured":"Gao K, Lin Z, Wen S, Jiang Y. Potassium channels and epilepsy. Acta Neurol Scand. 2022;146(6):699\u2013707. https:\/\/doi.org\/10.1111\/ane.13695.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1155_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1073858418763752","volume":"24","author":"Z Niday","year":"2018","unstructured":"Niday Z, Tzingounis AV. Potassium channel gain of function in epilepsy: an unresolved paradox. Neuroscientist. 2018;24(4):368\u201380. https:\/\/doi.org\/10.1177\/1073858418763752.","journal-title":"Neuroscientist"},{"issue":"1","key":"1155_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.nbd.2011.03.016","volume":"43","author":"F Sicca","year":"2011","unstructured":"Sicca F, Imbrici P, D\u2019Adamo MC, Moro F, Bonatti F, Brovedani P, Grottesi A, Guerrini R, Masi G, Santorelli FM, Pessia M. Autism with seizures and intellectual disability: possible causative role of gain-of-function of the inwardly-rectifying K+ channel Kir4.1. Neurobiol Dis. 2011;43(1):239\u201347. https:\/\/doi.org\/10.1016\/j.nbd.2011.03.016.","journal-title":"Neurobiol Dis"},{"issue":"7","key":"1155_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/ng1585","volume":"37","author":"W Du","year":"2005","unstructured":"Du W, Bautista JF, Yang H, Diez-Sampedro A, You SA, Wang L, Kotagal P, L\u00fcders HO, Shi J, Cui J, Richerson GB, Wang QK. Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder. Nat Genet. 2005;37(7):733\u20138. https:\/\/doi.org\/10.1038\/ng1585.","journal-title":"Nat Genet"},{"key":"1155_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev.physiol.65.092101.142734","volume":"65","author":"RB Robinson","year":"2003","unstructured":"Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol. 2003;65:453\u201380. https:\/\/doi.org\/10.1146\/annurev.physiol.65.092101.142734.","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"1155_CR12","doi-asserted-by":"publisher","first-page":"C893","DOI":"10.1152\/ajpcell.00709.2023","volume":"326","author":"C Celentano","year":"2024","unstructured":"Celentano C, Carotenuto L, Miceli F, Carleo G, Corrado B, Baroli G, Iervolino S, Vecchione R, Taglialatela M, Barrese V. Kv7 channel activation reduces brain endothelial cell permeability and prevents kainic acid-induced blood-brain barrier damage. Am J Physiol Cell Physiol. 2024;326(3):C893\u2013904. https:\/\/doi.org\/10.1152\/ajpcell.00709.2023.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"1155_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1152\/physrev.00011.2013","volume":"93","author":"EA Nagelhus","year":"2013","unstructured":"Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. Physiol Rev. 2013;93(4):1543\u201362. https:\/\/doi.org\/10.1152\/physrev.00011.2013.","journal-title":"Physiol Rev"},{"issue":"2","key":"1155_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.neuron.2014.12.042","volume":"85","author":"JS Trimmer","year":"2015","unstructured":"Trimmer JS. Subcellular localization of K+ channels in mammalian brain neurons: remarkable precision in the midst of extraordinary complexity. Neuron. 2015;85(2):238\u201356. https:\/\/doi.org\/10.1016\/j.neuron.2014.12.042.","journal-title":"Neuron"},{"issue":"12","key":"1155_CR15","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/nrd2983","volume":"8","author":"H Wulff","year":"2009","unstructured":"Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009;8(12):982\u20131001. https:\/\/doi.org\/10.1038\/nrd2983.","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"1155_CR16","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1007\/s00018-015-1948-5","volume":"72","author":"Q Kuang","year":"2015","unstructured":"Kuang Q, Purhonen P, Hebert H. Structure of potassium channels. Cell Mol Life Sci. 2015;72(19):3677\u201393. https:\/\/doi.org\/10.1007\/s00018-015-1948-5.","journal-title":"Cell Mol Life Sci"},{"key":"1155_CR17","unstructured":"Cooper EC. Potassium channels (including KCNQ) and epilepsy. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th ed. Bethesda: National Center for Biotechnology Information (US); 2012."},{"issue":"Suppl 2","key":"1155_CR18","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1111\/bph.16178","volume":"180","author":"SPH Alexander","year":"2023","unstructured":"Alexander SPH, Mathie AA, Peters JA, Veale EL, Striessnig J, Kelly E, Armstrong JF, Faccenda E, Harding SD, Davies JA, Aldrich RW, Attali B, Baggetta AM, Becirovic E, Biel M, Bill RM, Caceres AI, Catterall WA, Conner AC, Davies P, De Clerq K, Delling M, Di Virgilio F, Falzoni S, Fenske S, Fortuny-Gomez A, Fountain S, George C, Goldstein SAN, Grimm C, Grissmer S, Ha K, Hammelmann V, Hanukoglu I, Hu M, Ijzerman AP, Jabba SV, Jarvis M, Jensen AA, Jordt SE, Kaczmarek LK, Kellenberger S, Kennedy C, King B, Kitchen P, Liu Q, Lynch JW, Meades J, Mehlfeld V, Nicke A, Offermanns S, Perez-Reyes E, Plant LD, Rash L, Ren D, Salman MM, Sieghart W, Sivilotti LG, Smart TG, Snutch TP, Tian J, Trimmer JS, Van den Eynde C, Vriens J, Wei AD, Winn BT, Wulff H, Xu H, Yang F, Fang W, Yue L, Zhang X, Zhu M. The concise guide to PHARMACOLOGY 2023\/24: ion channels. Br J Pharmacol. 2023;180(Suppl 2):S145\u2013222. https:\/\/doi.org\/10.1111\/bph.16178.","journal-title":"Br J Pharmacol"},{"issue":"5187","key":"1155_CR19","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1126\/science.7973666","volume":"266","author":"E Ficker","year":"1994","unstructured":"Ficker E, Taglialatela M, Wible BA, Henley CM, Brown AM. Spermine and spermidine as gating molecules for inward rectifier K+ channels. Science. 1994;266(5187):1068\u201372. https:\/\/doi.org\/10.1126\/science.7973666.","journal-title":"Science"},{"issue":"22","key":"1155_CR20","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1002\/j.1460-2075.1995.tb00240.x","volume":"14","author":"M Taglialatela","year":"1995","unstructured":"Taglialatela M, Ficker E, Wible BA, Brown AM. C-terminus determinants for Mg2+ and polyamine block of the inward rectifier K+ channel IRK1. EMBO J. 1995;14(22):5532\u201341. https:\/\/doi.org\/10.1002\/j.1460-2075.1995.tb00240.x.","journal-title":"EMBO J"},{"issue":"3","key":"1155_CR21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1113\/jphysiol.1961.sp006738","volume":"157","author":"RM Eccles","year":"1961","unstructured":"Eccles RM, Libet B. Origin and blockade of the synaptic responses of curarized sympathetic ganglia. J Physiol. 1961;157(3):484\u2013503. https:\/\/doi.org\/10.1113\/jphysiol.1961.sp006738.","journal-title":"J Physiol"},{"issue":"4","key":"1155_CR22","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1073\/pnas.60.4.1304","volume":"60","author":"H Kobayashi","year":"1968","unstructured":"Kobayashi H, Libet B. Generation of slow postsynaptic potentials without increases in ionic conductance. Proc Natl Acad Sci USA. 1968;60(4):1304\u201311. https:\/\/doi.org\/10.1073\/pnas.60.4.1304.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3959","key":"1155_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1126\/science.170.3959.755","volume":"170","author":"FF Weight","year":"1970","unstructured":"Weight FF, Votava J. Slow synaptic excitation in sympathetic ganglion cells: evidence for synaptic inactivation of potassium conductance. Science. 1970;170(3959):755\u20138. https:\/\/doi.org\/10.1126\/science.170.3959.755.","journal-title":"Science"},{"issue":"5748","key":"1155_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/283673a0","volume":"283","author":"DA Brown","year":"1980","unstructured":"Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature. 1980;283(5748):673\u20136. https:\/\/doi.org\/10.1038\/283673a0.","journal-title":"Nature"},{"key":"1155_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev.physiol.59.1.483","volume":"59","author":"NV Marrion","year":"1997","unstructured":"Marrion NV. Control of M-current. Annu Rev Physiol. 1997;59:483\u2013504. https:\/\/doi.org\/10.1146\/annurev.physiol.59.1.483.","journal-title":"Annu Rev Physiol"},{"issue":"5","key":"1155_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1152\/physiol.00009.2011","volume":"26","author":"MV Soldovieri","year":"2011","unstructured":"Soldovieri MV, Miceli F, Taglialatela M. Driving with no brakes: molecular pathophysiology of Kv7 potassium channels. Physiology (Bethesda). 2011;26(5):365\u201376. https:\/\/doi.org\/10.1152\/physiol.00009.2011.","journal-title":"Physiology (Bethesda)"},{"issue":"19","key":"1155_CR27","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1523\/JNEUROSCI.0765-04.2004","volume":"24","author":"C Yue","year":"2004","unstructured":"Yue C, Yaari Y. KCNQ\/M channels control spike afterdepolarization and burst generation in hippocampal neurons. J Neurosci. 2004;24(19):4614\u201324. https:\/\/doi.org\/10.1523\/JNEUROSCI.0765-04.2004.","journal-title":"J Neurosci"},{"issue":"11","key":"1155_CR28","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nrn1785","volume":"6","author":"P Delmas","year":"2005","unstructured":"Delmas P, Brown DA. Pathways modulating neural KCNQ\/M (Kv7) potassium channels. Nat Rev Neurosci. 2005;6(11):850\u201362. https:\/\/doi.org\/10.1038\/nrn1785.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1155_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng0198-25","volume":"18","author":"NA Singh","year":"1998","unstructured":"Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, McHarg ML, Gagnon D, Rosales TO, Peiffer A, Anderson VE, Leppert M. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet. 1998;18(1):25\u20139. https:\/\/doi.org\/10.1038\/ng0198-25.","journal-title":"Nat Genet"},{"issue":"1","key":"1155_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ng0198-53","volume":"18","author":"C Charlier","year":"1998","unstructured":"Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, Leppert M. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet. 1998;18(1):53\u20135. https:\/\/doi.org\/10.1038\/ng0198-53.","journal-title":"Nat Genet"},{"issue":"5395","key":"1155_CR31","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1126\/science.282.5395.1890","volume":"282","author":"HS Wang","year":"1998","unstructured":"Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, McKinnon D. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998;282(5395):1890\u20133. https:\/\/doi.org\/10.1126\/science.282.5395.1890.","journal-title":"Science"},{"issue":"Pt 3","key":"1155_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1469-7793.2000.t01-2-00349.x","volume":"522","author":"AA Selyanko","year":"2000","unstructured":"Selyanko AA, Hadley JK, Wood IC, Abogadie FC, Jentsch TJ, Brown DA. Inhibition of KCNQ1-4 potassium channels expressed in mammalian cells via M1 muscarinic acetylcholine receptors. J Physiol. 2000;522(Pt 3):349\u201355. https:\/\/doi.org\/10.1111\/j.1469-7793.2000.t01-2-00349.x.","journal-title":"J Physiol"},{"issue":"12","key":"1155_CR33","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1523\/JNEUROSCI.23-12-05012.2003","volume":"23","author":"JK Hadley","year":"2003","unstructured":"Hadley JK, Passmore GM, Tatulian L, Al-Qatari M, Ye F, Wickenden AD, Brown DA. Stoichiometry of expressed KCNQ2\/KCNQ3 potassium channels and subunit composition of native ganglionic M channels deduced from block by tetraethylammonium. J Neurosci. 2003;23(12):5012\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-12-05012.2003.","journal-title":"J Neurosci"},{"issue":"3\u20134","key":"1155_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000515495","volume":"43","author":"K Springer","year":"2021","unstructured":"Springer K, Varghese N, Tzingounis AV. Flexible stoichiometry: implications for KCNQ2- and KCNQ3-associated neurodevelopmental disorders. Dev Neurosci. 2021;43(3\u20134):191\u2013200. https:\/\/doi.org\/10.1159\/000515495.","journal-title":"Dev Neurosci"},{"key":"1155_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.570588","volume":"11","author":"N Dirkx","year":"2020","unstructured":"Dirkx N, Miceli F, Taglialatela M, Weckhuysen S. The role of Kv7.2 in neurodevelopment: insights and gaps in our understanding. Front Physiol. 2020;11: 570588. https:\/\/doi.org\/10.3389\/fphys.2020.570588.","journal-title":"Front Physiol"},{"issue":"10","key":"1155_CR36","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1523\/JNEUROSCI.4206-13.2014","volume":"34","author":"A Battefeld","year":"2014","unstructured":"Battefeld A, Tran BT, Gavrilis J, Cooper EC, Kole MH. Heteromeric Kv7.2\/7.3 channels differentially regulate action potential initiation and conduction in neocortical myelinated axons. J Neurosci. 2014;34(10):3719\u201332. https:\/\/doi.org\/10.1523\/JNEUROSCI.4206-13.2014.","journal-title":"J Neurosci"},{"issue":"Pt 3","key":"1155_CR37","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1113\/jphysiol.2005.086835","volume":"566","author":"N Gu","year":"2005","unstructured":"Gu N, Vervaeke K, Hu H, Storm JF. Kv7\/KCNQ\/M and HCN\/h, but not KCa2\/SK channels, contribute to the somatic medium after-hyperpolarization and excitability control in CA1 hippocampal pyramidal cells. J Physiol. 2005;566(Pt 3):689\u2013715. https:\/\/doi.org\/10.1113\/jphysiol.2005.086835.","journal-title":"J Physiol"},{"issue":"10","key":"1155_CR38","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1523\/JNEUROSCI.4314-05.2006","volume":"26","author":"Z Pan","year":"2006","unstructured":"Pan Z, Kao T, Horvath Z, Lemos J, Sul JY, Cranstoun SD, Bennett V, Scherer SS, Cooper EC. A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon. J Neurosci. 2006;26(10):2599\u2013613. https:\/\/doi.org\/10.1523\/JNEUROSCI.4314-05.2006.","journal-title":"J Neurosci"},{"issue":"5","key":"1155_CR39","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1523\/JNEUROSCI.4512-03.2004","volume":"24","author":"JJ Devaux","year":"2004","unstructured":"Devaux JJ, Kleopa KA, Cooper EC, Scherer SS. KCNQ2 is a nodal K+ channel. J Neurosci. 2004;24(5):1236\u201344. https:\/\/doi.org\/10.1523\/JNEUROSCI.4512-03.2004.","journal-title":"J Neurosci"},{"issue":"3","key":"1155_CR40","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1523\/JNEUROSCI.3143-03.2004","volume":"24","author":"M Martire","year":"2004","unstructured":"Martire M, Castaldo P, D\u2019Amico M, Preziosi P, Annunziato L, Taglialatela M. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J Neurosci. 2004;24(3):592\u20137. https:\/\/doi.org\/10.1523\/JNEUROSCI.3143-03.2004.","journal-title":"J Neurosci"},{"issue":"1","key":"1155_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1152\/jn.00634.2006","volume":"97","author":"A Peretz","year":"2007","unstructured":"Peretz A, Sheinin A, Yue C, Degani-Katzav N, Gibor G, Nachman R, Gopin A, Tam E, Shabat D, Yaari Y, Attali B. Pre- and postsynaptic activation of M-channels by a novel opener dampens neuronal firing and transmitter release. J Neurophysiol. 2007;97(1):283\u201395. https:\/\/doi.org\/10.1152\/jn.00634.2006.","journal-title":"J Neurophysiol"},{"issue":"6604","key":"1155_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/384080a0","volume":"384","author":"MC Sanguinetti","year":"1996","unstructured":"Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature. 1996;384(6604):80\u20133. https:\/\/doi.org\/10.1038\/384080a0.","journal-title":"Nature"},{"issue":"1","key":"1155_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng0196-17","volume":"12","author":"Q Wang","year":"1996","unstructured":"Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Toubin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12(1):17\u201323. https:\/\/doi.org\/10.1038\/ng0196-17.","journal-title":"Nat Genet"},{"issue":"3","key":"1155_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0092-8674(00)80556-5","volume":"96","author":"C Kubisch","year":"1999","unstructured":"Kubisch C, Schroeder BC, Friedrich T, L\u00fctjohann B, El-Amraoui A, Marlin S, Petit C, Jentsch TJ. KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell. 1999;96(3):437\u201346. https:\/\/doi.org\/10.1016\/s0092-8674(00)80556-5.","journal-title":"Cell"},{"key":"1155_CR45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1146\/annurev-pharmtox-010617-052912","volume":"58","author":"V Barrese","year":"2018","unstructured":"Barrese V, Stott JB, Greenwood IA. KCNQ-encoded potassium channels as therapeutic targets. Annu Rev Pharmacol Toxicol. 2018;58:625\u201348. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010617-052912.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1155_CR46","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3389\/fphys.2020.01004","volume":"11","author":"J Malysz","year":"2020","unstructured":"Malysz J, Petkov GV. Detrusor smooth muscle KV7 channels: emerging new regulators of urinary bladder function. Front Physiol. 2020;11:1004. https:\/\/doi.org\/10.3389\/fphys.2020.01004.","journal-title":"Front Physiol"},{"issue":"3","key":"1155_CR47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1124\/jpet.109.162800","volume":"332","author":"FA Iannotti","year":"2010","unstructured":"Iannotti FA, Panza E, Barrese V, Viggiano D, Soldovieri MV, Taglialatela M. Expression, localization, and pharmacological role of Kv7 potassium channels in skeletal muscle proliferation, differentiation, and survival after myotoxic insults. J Pharmacol Exp Ther. 2010;332(3):811\u201320. https:\/\/doi.org\/10.1124\/jpet.109.162800.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1155_CR48","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1091\/mbc.E11-12-1044","volume":"24","author":"FA Iannotti","year":"2013","unstructured":"Iannotti FA, Barrese V, Formisano L, Miceli F, Taglialatela M. Specification of skeletal muscle differentiation by repressor element-1 silencing transcription factor (REST)-regulated Kv7.4 potassium channels. Mol Biol Cell. 2013;24(3):274\u201384. https:\/\/doi.org\/10.1091\/mbc.E11-12-1044.","journal-title":"Mol Biol Cell"},{"issue":"29","key":"1155_CR49","doi-asserted-by":"publisher","first-page":"22395","DOI":"10.1074\/jbc.M002378200","volume":"275","author":"C Lerche","year":"2000","unstructured":"Lerche C, Scherer CR, Seebohm G, Derst C, Wei AD, Busch AE, Steinmeyer K. Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. J Biol Chem. 2000;275(29):22395\u2013400. https:\/\/doi.org\/10.1074\/jbc.M002378200.","journal-title":"J Biol Chem"},{"issue":"31","key":"1155_CR50","doi-asserted-by":"publisher","first-page":"24089","DOI":"10.1074\/jbc.M003245200","volume":"275","author":"BC Schroeder","year":"2000","unstructured":"Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000;275(31):24089\u201395. https:\/\/doi.org\/10.1074\/jbc.M003245200.","journal-title":"J Biol Chem"},{"issue":"22","key":"1155_CR51","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1073\/pnas.1004644107","volume":"107","author":"AV Tzingounis","year":"2010","unstructured":"Tzingounis AV, Heidenreich M, Kharkovets T, Spitzmaul G, Jensen HS, Nicoll RA, Jentsch TJ. The KCNQ5 potassium channel mediates a component of the afterhyperpolarization current in mouse hippocampus. Proc Natl Acad Sci USA. 2010;107(22):10232\u20137. https:\/\/doi.org\/10.1073\/pnas.1004644107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1155_CR52","doi-asserted-by":"publisher","unstructured":"Lehman A, Thouta S, Mancini GMS, Naidu S, van Slegtenhorst M, McWalter K, Person R, Mwenifumbo J, Salvarinova R, CAUSES Study, EPGEN Study, Guella I, McKenzie MB, Datta A, Connolly MB, Kalkhoran SM, Poburko D, Friedman JM, Farrer MJ, Demos M, Desai S, Claydon T. Loss-of-function and gain-of-function mutations in KCNQ5 cause intellectual disability or epileptic encephalopathy. Am J Hum Genet. 2017;101(1):65\u201374. https:\/\/doi.org\/10.1016\/j.ajhg.2017.05.016.","DOI":"10.1016\/j.ajhg.2017.05.016"},{"issue":"15","key":"1155_CR53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116887119","volume":"119","author":"M Nappi","year":"2022","unstructured":"Nappi M, Barrese V, Carotenuto L, Lesca G, Labalme A, Ville D, Smol T, Rama M, Dieux- Coeslier A, Rivier-Ringenbach C, Soldovieri MV, Ambrosino P, Mosca I, Pusch M, Miceli F, Taglialatela M. Gain of function due to increased opening probability by two KCNQ5 pore variants causing developmental and epileptic encephalopathy. Proc Natl Acad Sci USA. 2022;119(15): e2116887119. https:\/\/doi.org\/10.1073\/pnas.2116887119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1155_CR54","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3389\/fphys.2020.00583","volume":"11","author":"GW Abbott","year":"2020","unstructured":"Abbott GW. KCNQs: ligand- and voltage-gated potassium channels. Front Physiol. 2020;11:583. https:\/\/doi.org\/10.3389\/fphys.2020.00583.","journal-title":"Front Physiol"},{"issue":"1","key":"1155_CR55","doi-asserted-by":"publisher","first-page":"6632","DOI":"10.1038\/s41467-023-42416-x","volume":"14","author":"D Ma","year":"2023","unstructured":"Ma D, Zheng Y, Li X, Zhou X, Yang Z, Zhang Y, Wang L, Zhang W, Fang J, Zhao G, Hou P, Nan F, Yang W, Su N, Gao Z, Guo J. Ligand activation mechanisms of human KCNQ2 channel. Nat Commun. 2023;14(1):6632. https:\/\/doi.org\/10.1038\/s41467-023-42416-x.","journal-title":"Nat Commun"},{"issue":"1","key":"1155_CR56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41422-020-00410-8","volume":"31","author":"X Li","year":"2021","unstructured":"Li X, Zhang Q, Guo P, Fu J, Mei L, Lv D, Wang J, Lai D, Ye S, Yang H, Guo J. Molecular basis for ligand activation of the human KCNQ2 channel. Cell Res. 2021;31(1):52\u201361. https:\/\/doi.org\/10.1038\/s41422-020-00410-8.","journal-title":"Cell Res"},{"issue":"2","key":"1155_CR57","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuron.2021.10.029","volume":"110","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Liu H, Chen Y, Dong S, Wang F, Wang S, Li GL, Shu Y, Xu F. Structural insights into the lipid and ligand regulation of a human neuronal KCNQ channel. Neuron. 2022;110(2):237-47.e4. https:\/\/doi.org\/10.1016\/j.neuron.2021.10.029.","journal-title":"Neuron"},{"issue":"1","key":"1155_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.molcel.2020.10.037","volume":"81","author":"T Li","year":"2021","unstructured":"Li T, Wu K, Yue Z, Wang Y, Zhang F, Shen H. Structural basis for the modulation of human KCNQ4 by small-molecule drugs. Mol Cell. 2021;81(1):25-37.e4. https:\/\/doi.org\/10.1016\/j.molcel.2020.10.037.","journal-title":"Mol Cell"},{"key":"1155_CR59","doi-asserted-by":"publisher","unstructured":"Nappi M, Alberini G, Berselli A, Roscioni A, Soldovieri MV, Barrese V, Weckhysen S, Chiu TGA, Scheffer IE, Benfenati F, Maragliano L, Miceli F, Taglialatela M. Constitutive opening of the Kv7.2 pore activation gate causes CNQ2-developmental encephalopathy. Preprint. bioRxiv 2024 https:\/\/doi.org\/10.1101\/2024.05.20.593680.","DOI":"10.1101\/2024.05.20.593680"},{"key":"1155_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.149218","volume":"689","author":"Y Huang","year":"2023","unstructured":"Huang Y, Ma D, Yang Z, Zhao Y, Guo J. Voltage-gated potassium channels KCNQs: structures, mechanisms, and modulations. Biochem Biophys Res Commun. 2023;689: 149218. https:\/\/doi.org\/10.1016\/j.bbrc.2023.149218.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"1155_CR61","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1085\/jgp.201812070","volume":"150","author":"CK Wang","year":"2018","unstructured":"Wang CK, Lamothe SM, Wang AW, Yang RY, Kurata HT. Pore- and voltage sensor-targeted KCNQ openers have distinct state-dependent actions. J Gen Physiol. 2018;150(12):1722\u201334. https:\/\/doi.org\/10.1085\/jgp.201812070.","journal-title":"J Gen Physiol"},{"issue":"8","key":"1155_CR62","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1111\/epi.16592","volume":"61","author":"R Kanyo","year":"2020","unstructured":"Kanyo R, Wang CK, Locskai LF, Li J, Allison WT, Kurata HT. Functional and behavioral signatures of Kv7 activator drug subtypes. Epilepsia. 2020;61(8):1678\u201390. https:\/\/doi.org\/10.1111\/epi.16592.","journal-title":"Epilepsia"},{"issue":"6","key":"1155_CR63","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/epi.17239","volume":"63","author":"SM Zuberi","year":"2022","unstructured":"Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, Pressler R, Auvin S, Samia P, Hirsch E, Galicchio S, Triki C, Snead OC, Wiebe S, Cross JH, Tinuper P, Scheffer IE, Perucca E, Mosh\u00e9 SL, Nabbout R. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1349\u201397. https:\/\/doi.org\/10.1111\/epi.17239.","journal-title":"Epilepsia"},{"key":"1155_CR64","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/epi.12984","volume":"56","author":"T Pisano","year":"2015","unstructured":"Pisano T, Numis AL, Heavin SB, Weckhuysen S, Angriman M, Suls A, Podesta B, Thibert RL, Shapiro KA, Guerrini R, Scheffer IE, Marini C, Cilio MR. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia. 2015;56:685\u201391. https:\/\/doi.org\/10.1111\/epi.12984.","journal-title":"Epilepsia"},{"issue":"12","key":"1155_CR65","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1111\/epi.13596","volume":"57","author":"TT Sands","year":"2016","unstructured":"Sands TT, Balestri M, Bellini G, Mulkey SB, Danhaive O, Bakken EH, Taglialatela M, Oldham MS, Vigevano F, Holmes GL, Cilio MR. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. Epilepsia. 2016;57(12):2019\u201330. https:\/\/doi.org\/10.1111\/epi.13596.","journal-title":"Epilepsia"},{"key":"1155_CR66","unstructured":"Miceli F, Soldovieri MV, Weckhuysen S, et al. KCNQ2-Related Disorders. 2010 Apr 27 [Updated 2022 May 19]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK32534\/."},{"key":"1155_CR67","unstructured":"Pressler R, Taglialatela M, Plouin P, Hassn H. Self-limited (familial) neonatal epilepsy. In: Engel J Jr, Mosh\u00e9 SL, editors, Epilepsy. A Comprehensive Textbook, 3rd edition, Volume 3, Chapter 275, Philadephia: Wolters Kluwer 2024. p. 2817\u201326"},{"key":"1155_CR68","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.seizure.2018.05.005","volume":"59","author":"K Kothur","year":"2018","unstructured":"Kothur K, Holman K, Farnsworth E, Ho G, Lorentzos M, Troedson C, Gupta S, Webster R, Procopis PG, Menezes MP, Antony J, Ardern-Holmes S, Dale RC, Christodoulou J, Gill D, Bennetts B. Diagnostic yield of targeted massively parallel sequencing in children with epileptic encephalopathy. Seizure. 2018;59:132\u201340. https:\/\/doi.org\/10.1016\/j.seizure.2018.05.005.","journal-title":"Seizure."},{"issue":"3","key":"1155_CR69","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/epi4.12353","volume":"4","author":"A Lauritano","year":"2019","unstructured":"Lauritano A, Moutton S, Longobardi E, Tran Mau-Them F, Laudati G, Nappi P, Soldovieri MV, Ambrosino P, Cataldi M, Jouan T, Lehalle D, Maurey H, Philippe C, Miceli F, Vitobello A, Taglialatela M. A novel homozygous KCNQ3 loss-of-function variant causes non- syndromic intellectual disability and neonatal-onset pharmacodependent epilepsy. Epilepsia Open. 2019;4(3):464\u201375. https:\/\/doi.org\/10.1002\/epi4.12353.","journal-title":"Epilepsia Open."},{"issue":"7","key":"1155_CR70","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00424-020-02404-2","volume":"472","author":"P Nappi","year":"2020","unstructured":"Nappi P, Miceli F, Soldovieri MV, Ambrosino P, Barrese V, Taglialatela M. Epileptic channelopathies caused by neuronal Kv7 (KCNQ) channel dysfunction. Pflugers Arch. 2020;472(7):881\u201398. https:\/\/doi.org\/10.1007\/s00424-020-02404-2.","journal-title":"Pflugers Arch"},{"issue":"11","key":"1155_CR71","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1073\/pnas.1216867110","volume":"110","author":"F Miceli","year":"2013","unstructured":"Miceli F, Soldovieri MV, Ambrosino P, Barrese V, Migliore M, Cilio MR, Taglialatela M. Genotype-phenotype correlations in neonatal epilepsies caused by mutations in the voltage sensor of K(v)7.2 potassium channel subunits. Proc Natl Acad Sci USA. 2013;110(11):4386\u201391. https:\/\/doi.org\/10.1073\/pnas.1216867110.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1155_CR72","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/ana.24080","volume":"75","author":"G Orhan","year":"2014","unstructured":"Orhan G, Bock M, Schepers D, Ilina EI, Reichel SN, L\u00f6ffler H, Jezutkovic N, Weckhuysen S, Mandelstam S, Suls A, Danker T, Guenther E, Scheffer IE, De Jonghe P, Lerche H, Maljevic S. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. Ann Neurol. 2014;75(3):382\u201394. https:\/\/doi.org\/10.1002\/ana.24080.","journal-title":"Ann Neurol"},{"issue":"1","key":"1155_CR73","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1111\/epi.13601","volume":"58","author":"JJ Millichap","year":"2017","unstructured":"Millichap JJ, Miceli F, De Maria M, Keator C, Joshi N, Tran B, Soldovieri MV, Ambrosino P, Shashi V, Mikati MA, Cooper EC, Taglialatela M. Infantile spasms and encephalopathy without preceding neonatal seizures caused by KCNQ2 R198Q, a gain-of-function variant. Epilepsia. 2017;58(1):e10\u20135. https:\/\/doi.org\/10.1111\/epi.13601.","journal-title":"Epilepsia"},{"issue":"3","key":"1155_CR74","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/epi.13676","volume":"58","author":"SB Mulkey","year":"2017","unstructured":"Mulkey SB, Ben-Zeev B, Nicolai J, Carroll JL, Gr\u00f8nborg S, Jiang YH, Joshi N, Kelly M, Koolen DA, Mikati MA, Park K, Pearl PL, Scheffer IE, Spillmann RC, Taglialatela M, Vieker S, Weckhuysen S, Cooper EC, Cilio MR. Neonatal nonepileptic myoclonus is a prominent clinical feature of KCNQ2 gain-of-function variants R201C and R201H. Epilepsia. 2017;58(3):436\u201345. https:\/\/doi.org\/10.1111\/epi.13676.","journal-title":"Epilepsia"},{"issue":"2","key":"1155_CR75","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.25522","volume":"86","author":"TT Sands","year":"2019","unstructured":"Sands TT, Miceli F, Lesca G, Beck AE, Sadleir LG, Arrington DK, Sch\u00f6newolf-Greulich B, Moutton S, Lauritano A, Nappi P, Soldovieri MV, Scheffer IE, Mefford HC, Stong N, Heinzen EL, Goldstein DB, Perez AG, Kossoff EH, Stocco A, Sullivan JA, Shashi V, Gerard B, Francannet C, Bisgaard AM, T\u00fcmer Z, Willems M, Rivier F, Vitobello A, Thakkar K, Rajan DS, Barkovich AJ, Weckhuysen S, Cooper EC, Taglialatela M, Cilio MR. Autism and developmental disability caused by KCNQ3 gain-of-function variants. Ann Neurol. 2019;86(2):181\u201392. https:\/\/doi.org\/10.1002\/ana.25522.","journal-title":"Ann Neurol"},{"issue":"2","key":"1155_CR76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hipo.23587","volume":"34","author":"S Jiang","year":"2024","unstructured":"Jiang S, Liu B, Lin K, Li L, Li R, Tan S, Zhang X, Jiang L, Ni H, Wang Y, Ding H, Hu J, Qian H, Ge R. Impacted spike frequency adaptation associated with reduction of KCNQ2\/3 exacerbates seizure activity in temporal lobe epilepsy. Hippocampus. 2024;34(2):58\u201372. https:\/\/doi.org\/10.1002\/hipo.23587.","journal-title":"Hippocampus"},{"issue":"3","key":"1155_CR77","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0920-1211(95)00101-8","volume":"23","author":"A Rostock","year":"1996","unstructured":"Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, L\u00f6scher W, H\u00f6nack D, White HS, Wolf HH. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 1996;23(3):211\u201323. https:\/\/doi.org\/10.1016\/0920-1211(95)00101-8.","journal-title":"Epilepsy Res"},{"key":"1155_CR78","unstructured":"Hackethal V. Anticonvulsant Potiga Discontinued in June 2017. Neurology Live. June 15, 2017. https:\/\/www.neurologylive.com\/view\/anticonvulsant-potiga-discontinued-june-2017."},{"key":"1155_CR79","unstructured":"Tandy MD, Cadieux JA, Namdari R. Using modified QbD to develop a novel pediatric formulation of ezogabine. Pharm Technol. 2021;45:44\u20139. https:\/\/www.pharmtech.com\/view\/using-modified-qbd-to-develop-a-novelpediatric-formulation-of-ezogabine. Accessed 15 Aug 2024."},{"key":"1155_CR80","unstructured":"Clinicaltrials.gov. XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (NCT04639310). https:\/\/www.clinicaltrials.gov\/study\/NCT04639310?term=XEN496&rank=2. Accessed 17 August 2024."},{"issue":"2\u20133","key":"1155_CR81","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s0014-2999(97)01249-1","volume":"336","author":"C Rundfeldt","year":"1997","unstructured":"Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol. 1997;336(2\u20133):243\u20139. https:\/\/doi.org\/10.1016\/s0014-2999(97)01249-1.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1155_CR82","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0920-1211(98)00131-4","volume":"35","author":"C Rundfeldt","year":"1999","unstructured":"Rundfeldt C. Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells. Epilepsy Res. 1999;35(2):99\u2013107. https:\/\/doi.org\/10.1016\/s0920-1211(98)00131-4.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1155_CR83","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1124\/mol.58.3.591","volume":"58","author":"AD Wickenden","year":"2000","unstructured":"Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2\/Q3 potassium channels. Mol Pharmacol. 2000;58(3):591\u2013600. https:\/\/doi.org\/10.1124\/mol.58.3.591.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"1155_CR84","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","volume":"53","author":"MJ Gunthorpe","year":"2012","unstructured":"Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012;53(3):412\u201324. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03365.x.","journal-title":"Epilepsia"},{"issue":"4","key":"1155_CR85","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1152\/jn.00564.2020","volume":"125","author":"N Varghese","year":"2021","unstructured":"Varghese N, Lauritano A, Taglialatela M, Tzingounis AV. KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons. J Neurophysiol. 2021;125(4):1440\u20139. https:\/\/doi.org\/10.1152\/jn.00564.2020.","journal-title":"J Neurophysiol"},{"key":"1155_CR86","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1007\/s10072-023-06955-x","volume":"44","author":"A Zahra","year":"2023","unstructured":"Zahra A, Liu R, Wang J, Wu J. Identifying the mechanism of action of the Kv7 channel opener, retigabine in the treatment of epilepsy. Neurol Sci. 2023;44:3819\u201325. https:\/\/doi.org\/10.1007\/s10072-023-06955-x.","journal-title":"Neurol Sci"},{"issue":"5","key":"1155_CR87","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a022780","volume":"6","author":"MA Rogawski","year":"2016","unstructured":"Rogawski MA, L\u00f6scher W, Rho JM. Mechanisms of action of antiseizure drugs and the ketogenic diet. Cold Spring Harb Perspect Med. 2016;6(5): a022780. https:\/\/doi.org\/10.1101\/cshperspect.a022780.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1155_CR88","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1074\/jbc.M115.683185","volume":"291","author":"R Syeda","year":"2016","unstructured":"Syeda R, Santos JS, Montal M. The sensorless pore module of voltage-gated K+ channel family 7 embodies the target site for the anticonvulsant retigabine. J Biol Chem. 2016;291:2931\u20137. https:\/\/doi.org\/10.1074\/jbc.M115.683185.","journal-title":"J Biol Chem"},{"issue":"2","key":"1155_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150095","volume":"11","author":"Y Ihara","year":"2016","unstructured":"Ihara Y, Tomonoh Y, Deshimaru M, Zhang B, Uchida T, Ishii A, Hirose S. Retigabine, a Kv7.2\/Kv7.3-channel opener, attenuates drug-induced seizures in knock-in mice harboring Kcnq2 mutations. PLoS ONE. 2016;11(2): e0150095. https:\/\/doi.org\/10.1371\/journal.pone.0150095.","journal-title":"PLoS ONE"},{"key":"1155_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109798","volume":"156","author":"SH Wong","year":"2024","unstructured":"Wong SH, Liou YM, Yang JJ, Lee IC. KCNQ2 mutations cause unique neonatal behavior arrests without motor seizures: functional characterization. Epilepsy Behav. 2024;156: 109798. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109798.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1155_CR91","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/epi.12950","volume":"56","author":"M Treven","year":"2015","unstructured":"Treven M, Koenig X, Assadpour E, Gantumur E, Meyer C, Hilber K, Boehm S, Kubista H. The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors. Epilepsia. 2015;56(4):647\u201357. https:\/\/doi.org\/10.1111\/epi.12950.","journal-title":"Epilepsia"},{"issue":"7","key":"1155_CR92","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2165\/00023210-200620070-00005","volume":"20","author":"GL Plosker","year":"2006","unstructured":"Plosker GL, Scott LJ. Retigabine: in partial seizures. CNS Drugs. 2006;20(7):601\u20138. https:\/\/doi.org\/10.2165\/00023210-200620070-00005. (discussion 609\u2013610).","journal-title":"CNS Drugs"},{"issue":"12","key":"1155_CR93","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1055\/s-0031-1300346","volume":"50","author":"C Rundfeldt","year":"2000","unstructured":"Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung. 2000;50(12):1063\u201370. https:\/\/doi.org\/10.1055\/s-0031-1300346.","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"1155_CR94","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/epi.165","volume":"61","author":"KE Thomson","year":"2020","unstructured":"Thomson KE, Metcalf CS, Newell TG, Huff J, Edwards SF, West PJ, Wilcox KS. Evaluation of subchronic administration of antiseizure drugs in spontaneously seizing rats. Epilepsia. 2020;61(6):1301\u201311. https:\/\/doi.org\/10.1111\/epi.165.","journal-title":"Epilepsia"},{"key":"1155_CR95","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuroscience.2021.03.029","volume":"463","author":"BS Barker","year":"2021","unstructured":"Barker BS, Spampanato J, McCarren HS, Berger K, Jackson CE, Yeung DT, Dudek FE, McDonough JH. The K(v)7 modulator, retigabine, is an efficacious antiseizure drug for delayed treatment of organophosphate-induced status epilepticus. Neuroscience. 2021;463:143\u201358. https:\/\/doi.org\/10.1016\/j.neuroscience.2021.03.029.","journal-title":"Neuroscience"},{"issue":"1","key":"1155_CR96","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/epi4.12550","volume":"7","author":"CS Metcalf","year":"2022","unstructured":"Metcalf CS, Vanegas F, Underwood T, Johnson K, West PJ, Smith MD, Wilcox KS. Screening of prototype antiseizure and anti-inflammatory compounds in the Theiler\u2019s murine encephalomyelitis virus model of epilepsy. Epilepsia Open. 2022;7(1):46\u201358. https:\/\/doi.org\/10.1002\/epi4.12550.","journal-title":"Epilepsia Open."},{"key":"1155_CR97","doi-asserted-by":"publisher","unstructured":"Vigil FA, Bozdemir E, Bugay V, Chun SH, Hobbs M, Sanchez I, Hastings SD, Veraza RJ, Holstein DM, Sprague SM, M Carver C, Cavazos JE, Brenner R, Lechleiter JD, Shapiro MS. Prevention of brain damage after traumatic brain injury by pharmacological enhancement of KCNQ (Kv7, \"M-type\") K+ currents in neurons. J Cereb Blood Flow Metab. 2020;40(6):1256\u201373. https:\/\/doi.org\/10.1177\/0271678X19857818.","DOI":"10.1177\/0271678X19857818"},{"issue":"3","key":"1155_CR98","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s13311-023-01361-9","volume":"20","author":"FA Vigil","year":"2023","unstructured":"Vigil FA, Belchior H, Bugay V, Bazaldua II, Stoja A, Dantas DC, Chun SH, Farmer A, Bozdemir E, Holstein DM, Cavazos JE, Lechleiter JD, Brenner R, Shapiro MS. Acute treatment with the M-channel (K(v)7, KCNQ) opener retigabine reduces the long-term effects of repetitive blast traumatic brain injuries. Neurotherapeutics. 2023;20(3):853\u201369. https:\/\/doi.org\/10.1007\/s13311-023-01361-9.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"1155_CR99","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0014-2999(96)00073-8","volume":"303","author":"C Tober","year":"1996","unstructured":"Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol. 1996;303(3):163\u20139. https:\/\/doi.org\/10.1016\/0014-2999(96)00073-8.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1155_CR100","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/epi4.12354","volume":"4","author":"CS Metcalf","year":"2019","unstructured":"Metcalf CS, Huff J, Thomson KE, Johnson K, Edwards SF, Wilcox KS. Evaluation of antiseizure drug efficacy and tolerability in the rat lamotrigine-resistant amygdala kindling model. Epilepsia Open. 2019;4(3):452\u201363. https:\/\/doi.org\/10.1002\/epi4.12354.","journal-title":"Epilepsia Open."},{"issue":"2","key":"1155_CR101","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/00912700222011210","volume":"42","author":"GM Ferron","year":"2002","unstructured":"Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol. 2002;42(2):175\u201382. https:\/\/doi.org\/10.1177\/00912700222011210.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1155_CR102","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1067\/mcp.2003.12","volume":"73","author":"R Hermann","year":"2003","unstructured":"Hermann R, Ferron GM, Erb K, Knebel N, Ruus P, Paul J, Richards L, Cnota HP, Troy S. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther. 2003;73(1):61\u201370. https:\/\/doi.org\/10.1067\/mcp.2003.12.","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"1155_CR103","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.2165\/11594640-000000000-00000","volume":"71","author":"C Fattore","year":"2011","unstructured":"Fattore C, Perucca E. Novel medications for epilepsy. Drugs. 2011;71(16):2151\u201378. https:\/\/doi.org\/10.2165\/11594640-000000000-00000.","journal-title":"Drugs"},{"key":"1155_CR104","unstructured":"Potiga (ezogabine) tablets, Prescribing Information (updated 15 March 2012). https:\/\/www.drugs.com\/pro\/potiga.html#s-34092-7. Accessed 14 June 2024."},{"issue":"4","key":"1155_CR105","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/15748847113089990053","volume":"8","author":"DJ Tompson","year":"2013","unstructured":"Tompson DJ, Crean CS. Clinical pharmacokinetics of retigabine\/ezogabine. Curr Clin Pharmacol. 2013;8(4):319\u201331. https:\/\/doi.org\/10.2174\/15748847113089990053.","journal-title":"Curr Clin Pharmacol"},{"issue":"2","key":"1155_CR106","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40120-022-00343-x","volume":"11","author":"R Namdari","year":"2022","unstructured":"Namdari R, Luzon C, Cadieux JA, Leung J, Beatch GN. Pharmacokinetics of XEN496, a novel pediatric formulation of ezogabine, under fed and fasted conditions: a phase 1 trial. Neurol Ther. 2022;11(2):781\u201396. https:\/\/doi.org\/10.1007\/s40120-022-00343-x.","journal-title":"Neurol Ther."},{"issue":"5","key":"1155_CR107","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0090-9556(24)15258-0","volume":"27","author":"R Hempel","year":"1999","unstructured":"Hempel R, Schupke H, McNeilly PJ, Heinecke K, Kronbach C, Grunwald C, Zimmermann G, Griesinger C, Engel J, Kronbach T. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos. 1999;27(5):613\u201322.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1155_CR108","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2174\/1574884708666131111192311","volume":"9","author":"DJ Tompson","year":"2014","unstructured":"Tompson DJ, Crean CS. The interaction potential of retigabine (ezogabine) with other antiepileptic drugs. Curr Clin Pharmacol. 2014;9(2):148\u201356. https:\/\/doi.org\/10.2174\/1574884708666131111192311.","journal-title":"Curr Clin Pharmacol"},{"issue":"11","key":"1155_CR109","doi-asserted-by":"publisher","first-page":"847","DOI":"10.5414\/CP201916","volume":"51","author":"CS Crean","year":"2013","unstructured":"Crean CS, Tompson DJ, Buraglio M. The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent. Int J Clin Pharmacol Ther. 2013;51(11):847\u201353. https:\/\/doi.org\/10.5414\/CP201916.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1155_CR110","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/CPAA.S64131","volume":"6","author":"DJ Tompson","year":"2014","unstructured":"Tompson DJ, Crean CS, Buraglio M, Arumugham T. Lack of effect of ezogabine\/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study. Clin Pharmacol. 2014;6:149\u201359. https:\/\/doi.org\/10.2147\/CPAA.S64131.","journal-title":"Clin Pharmacol"},{"issue":"15","key":"1155_CR111","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/01.wnl.0000259034.45049.00","volume":"68","author":"RJ Porter","year":"2007","unstructured":"Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM, 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68(15):1197\u2013204. https:\/\/doi.org\/10.1212\/01.wnl.0000259034.45049.00.","journal-title":"Neurology"},{"issue":"20","key":"1155_CR112","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","volume":"75","author":"MJ Brodie","year":"2010","unstructured":"Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, Nohria V, Mansbach H, RESTORE 2 Study Group. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology. 2010;75(20):1817\u201324. https:\/\/doi.org\/10.1212\/WNL.0b013e3181fd6170.","journal-title":"Neurology"},{"issue":"18","key":"1155_CR113","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","volume":"76","author":"JA French","year":"2011","unstructured":"French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, Mansbach H, Nohria V, RESTORE 1\/Study 301 Investigators. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76(18):1555\u201363. https:\/\/doi.org\/10.1212\/WNL.0b013e3182194bd3.","journal-title":"Neurology"},{"key":"1155_CR114","doi-asserted-by":"publisher","unstructured":"Gil-Nagel A, Brodie MJ, Leroy R, Cyr T, Hall S, Castiglia M, Twomey C, VanLandingham . Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies. Epilepsy Res. 2012;102(1\u20132):117\u201321. https:\/\/doi.org\/10.1016\/j.eplepsyres.2012.05.007.","DOI":"10.1016\/j.eplepsyres.2012.05.007"},{"issue":"7","key":"1155_CR115","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1111\/epi.17627","volume":"64","author":"D Knight","year":"2023","unstructured":"Knight D, Mahida S, Kelly M, Poduri A, Olson HE. Ezogabine impacts seizures and development in patients with KCNQ2 developmental and epileptic encephalopathy. Epilepsia. 2023;64(7):e143\u20137. https:\/\/doi.org\/10.1111\/epi.17627.","journal-title":"Epilepsia"},{"key":"1155_CR116","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000096","volume":"2","author":"JJ Millichap","year":"2016","unstructured":"Millichap JJ, Park KL, Tsuchida T, Ben-Zeev B, Carmant L, Flamini R, et al. KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet. 2016;2: e96. https:\/\/doi.org\/10.1212\/NXG.0000000000000096.","journal-title":"Neurol Genet."},{"issue":"5","key":"1155_CR117","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1684\/epd.2021.1315","volume":"23","author":"A Nissenkorn","year":"2021","unstructured":"Nissenkorn A, Kornilov P, Peretz A, Blumkin L, Heimer G, Ben-Zeev B, et al. Personalized treatment with retigabine for pharmacoresistant epilepsy arising from a pathogenic variant in the KCNQ2 selectivity filter. Epileptic Disord. 2021;23(5):695\u2013705. https:\/\/doi.org\/10.1684\/epd.2021.1315.","journal-title":"Epileptic Disord"},{"key":"1155_CR118","unstructured":"Butterfield N, Harden C, Grayson C, Xu Y, Pimstone S, Millichap JJ Design of a clinical trial to determine the efficacy of XEN496 in KCNQ2-developmental and epileptic encephalopathy (KCNQ2-DEE). Xenon Pharmaceuticals Inc. Scientific Exhibit, presented at: American Epilepsy Society Annual Meeting; December 2\u20136, 2022, Nashville. https:\/\/www.xenon-pharma.com\/wp-content\/uploads\/2022\/12\/Butterfield2FinalWeb.pdf. Accessed 17 Dec 2024."},{"key":"1155_CR119","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.yebeh.2015.12.034","volume":"56","author":"RD Nass","year":"2016","unstructured":"Nass RD, Kurth C, Kull A, Graf W, Kasper B, Hamer HM, Strzelczyk A, Elger CE, Steinhoff BJ, Surges R, Rosenow F. Adjunctive retigabine in refractory focal epilepsy: postmarketing experience at four tertiary epilepsy care centers in Germany. Epilepsy Behav. 2016;56:54\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2015.12.034.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"1155_CR120","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.seizure.2014.08.001","volume":"23","author":"T Wehner","year":"2014","unstructured":"Wehner T, Chinnasami S, Novy J, Bell GS, Duncan JS, Sander JW. Long term retention of retigabine in a cohort of people with drug resistant epilepsy. Seizure. 2014;23(10):878\u201381. https:\/\/doi.org\/10.1016\/j.seizure.2014.08.001.","journal-title":"Seizure."},{"issue":"3","key":"1155_CR121","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1113\/JP277021","volume":"597","author":"NR Tykocki","year":"2019","unstructured":"Tykocki NR, Heppner TJ, Dalsgaard T, Bonev AD, Nelson MT. The KV 7 channel activator retigabine suppresses mouse urinary bladder afferent nerve activity without affecting detrusor smooth muscle K+ channel currents. J Physiol. 2019;597(3):935\u201350. https:\/\/doi.org\/10.1113\/JP277021.","journal-title":"J Physiol"},{"issue":"4","key":"1155_CR122","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.drudis.2013.12.003","volume":"19","author":"JB Stott","year":"2014","unstructured":"Stott JB, Jepps TA, Greenwood IA. K(V)7 potassium channels: a new therapeutic target in smooth muscle disorders. Drug Discov Today. 2014;19(4):413\u201324. https:\/\/doi.org\/10.1016\/j.drudis.2013.12.003.","journal-title":"Drug Discov Today"},{"issue":"5 Pt 1","key":"1155_CR123","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1097\/01.ju.0000138155.33749.f4","volume":"172","author":"T Streng","year":"2004","unstructured":"Streng T, Christoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol. 2004;172(5 Pt 1):2054\u20138. https:\/\/doi.org\/10.1097\/01.ju.0000138155.33749.f4.","journal-title":"J Urol"},{"key":"1155_CR124","unstructured":"Anonimous. Retigabine: blue skin discoloration and retinal pigment abnormalities. Prescrire Int. 2013;22(143):269."},{"issue":"9","key":"1155_CR125","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jamadermatol.2013.8895","volume":"150","author":"T Garin Shkolnik","year":"2014","unstructured":"Garin Shkolnik T, Feuerman H, Didkovsky E, Kaplan I, Bergman R, Pavlovsky L, Hodak E. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol. 2014;150(9):984\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2013.8895.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1155_CR126","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2042098614560736","volume":"6","author":"S Clark","year":"2015","unstructured":"Clark S, Antell A, Kaufman K. New antiepileptic medication linked to blue discoloration of the skin and eyes. Ther Adv Drug Saf. 2015;6(1):15\u20139. https:\/\/doi.org\/10.1177\/2042098614560736.","journal-title":"Ther Adv Drug Saf."},{"key":"1155_CR127","doi-asserted-by":"publisher","unstructured":"Brickel N, Hewett K, Rayner K, McDonald S, De\u2019Ath J, Daniluk J, Joshi K, Boll MC, Tiamkao S, Vorobyeva O, Cooper J. Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events. Epilepsy Behav. 2020;102:106580. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106580.","DOI":"10.1016\/j.yebeh.2019.106580"},{"key":"1155_CR128","unstructured":"European Medicines Agency. Trobalt. EPAR- Product Information (last updated December 19, 2018). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trobalt-epar-product-information_en.pdf. Accessed 20 Aug 2024."},{"issue":"2","key":"1155_CR129","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1021\/acs.chemrestox.8b00313","volume":"32","author":"MR Groseclose","year":"2019","unstructured":"Groseclose MR, Castellino S. An investigation into retigabine (ezogabine) associated dyspigmentation in rat eyes by MALDI imaging mass spectrometry. Chem Res Toxicol. 2019;32(2):294\u2013303. https:\/\/doi.org\/10.1021\/acs.chemrestox.8b00313.","journal-title":"Chem Res Toxicol"},{"issue":"16","key":"1155_CR130","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202200262","volume":"17","author":"KW Wurm","year":"2022","unstructured":"Wurm KW, Bartz FM, Schulig L, Bodtke A, Bednarski PJ, Link A. Carba analogues of flupirtine and retigabine with improved oxidation resistance and reduced risk of quinoid metabolite formation. ChemMedChem. 2022;17(16): e202200262. https:\/\/doi.org\/10.1002\/cmdc.202200262.","journal-title":"ChemMedChem"},{"issue":"16","key":"1155_CR131","doi-asserted-by":"publisher","first-page":"11340","DOI":"10.1021\/acs.jmedchem.2c00911","volume":"65","author":"S Musella","year":"2022","unstructured":"Musella S, Carotenuto L, Iraci N, Baroli G, Ciaglia T, Nappi P, Basilicata MG, Salviati E, Barrese V, Vestuto V, Pignataro G, Pepe G, Sommella E, Di Sarno V, Manfra M, Campiglia P, Gomez-Monterrey I, Bertamino A, Taglialatela M, Ostacolo C, Miceli F. Beyond retigabine: design, synthesis, and pharmacological characterization of a potent and chemically stable neuronal kv7 channel activator with anticonvulsant activity. Med Chem. 2022;65(16):11340\u201364. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00911.","journal-title":"Med Chem"},{"key":"1155_CR132","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ebcr.2017.01.001","volume":"7","author":"SV Mathias","year":"2017","unstructured":"Mathias SV, Abou-Khalil BW. Ezogabine skin discoloration is reversible after discontinuation. Epilepsy Behav Case Rep. 2017;7:61\u20133. https:\/\/doi.org\/10.1016\/j.ebcr.2017.01.001.","journal-title":"Epilepsy Behav Case Rep."},{"key":"1155_CR133","doi-asserted-by":"publisher","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, White HS.. Progress report on new antiepileptic drugs: A summary of the thirteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIII). I. Drugs in preclinical and early clinical development. Epilepsia. 2017;58(2):181\u2013221. https:\/\/doi.org\/10.1111\/epi.13634.","DOI":"10.1111\/epi.13634"},{"key":"1155_CR134","unstructured":"Asset Purchase Agreement. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1582313\/000156459017015414\/xene- ex102_64.htm. Accessed 20 Aug 2024."},{"key":"1155_CR135","doi-asserted-by":"publisher","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new medications for seizures and epilepsy: a summary of the seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII): II. Drugs in more advanced clinical development. Epilepsia. 2024;65:2858\u201382. https:\/\/doi.org\/10.1111\/epi.18075.","DOI":"10.1111\/epi.18075"},{"key":"1155_CR136","doi-asserted-by":"publisher","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the fourteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018;59 (10):1811\u201341. https:\/\/doi.org\/10.1111\/epi.14557.","DOI":"10.1111\/epi.14557"},{"key":"1155_CR137","doi-asserted-by":"publisher","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the fifteenth Eilat conference on new antiepileptic drugs and devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia. 2020;61:2340\u201364. https:\/\/doi.org\/10.1111\/epi.16725.","DOI":"10.1111\/epi.16725"},{"key":"1155_CR138","doi-asserted-by":"publisher","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the sixteenth Eilat conference on new antiepileptic drugs and devices (EILAT XVI): II. Drugs in more advanced clinical development. Epilepsia. 2022;63(11):2883\u2013910. https:\/\/doi.org\/10.1111\/epi.17376.","DOI":"10.1111\/epi.17376"},{"key":"1155_CR139","doi-asserted-by":"publisher","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new medications for seizures and epilepsy: a summary of the seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII): I. Drugs in preclinical and early clinical development. Epilepsia 2024;65:2831\u201357. https:\/\/doi.org\/10.1111\/epi.18056.","DOI":"10.1111\/epi.18056"},{"key":"1155_CR140","unstructured":"Dean R, Lin S, Bankar G, Khakh K, Mezeyova J, Li J, Lindgren A, Weishaupt N, Sojo L, Pimstone S, Cohen CJ, Empfield J, Goodchild SJ, Johnson JP Jr Preclinical in vitro and in vivo comparison of the KV 7 activator XEN1101 with ezogabine. Poster presented virtually at the American Epilepsy Society Annual Meeting, December 4-8, 2020. https:\/\/www.xenon-pharma.com\/wp-content\/uploads\/2020\/12\/Dean_AES2020_654_FINALjr.pdf. Accessed 10 Sept 2024."},{"issue":"8","key":"1155_CR141","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1038\/s41401-023-01073-y","volume":"44","author":"G-M Yang","year":"2023","unstructured":"Yang G-M, Tian F-Y, Shen Y-W, Yang C-Y, Yuan H, Li P, Gao Z-B. Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy. Acta Pharmacol Sin. 2023;44(8):1589\u201399. https:\/\/doi.org\/10.1038\/s41401-023-01073-y.","journal-title":"Acta Pharmacol Sin"},{"key":"1155_CR142","unstructured":"Goldberg YP. XEN1101, a novel modulator of Kv7.2\/3 for the treatment of epilepsy. Slide presentation at the Epilepsy Foundation Pipeline Conference, San Francisco, February 22-23, 2018. https:\/\/www.xenon-pharma.com\/wp-content\/uploads\/2018\/05\/XEN1101_EpilepsyFoundationPresentation_February2018.pdf. Accessed 20 Aug 2024."},{"key":"1155_CR143","unstructured":"Aycardi E, Namdari R, Cadieux J, Kato H, Leung C, Goldberg YP, Pimstone SN, Sherrington R, Cohen CJ, Empfield J, Crean C, Beatch GN. A first-in-human study to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of a novel small molecule KV 7.2\/7.3 positive allosteric modulator (XEN1101) in healthy subjects. Poster presented at the 72nd Annual Meeting of the American Epilepsy Society, New Orleans, LA, November 30\u2013December 4, 2018. https:\/\/www.xenon-pharma.com\/wp-content\/uploads\/2018\/12\/Aycardi-42x63_FINAL.pdf. Accessed 20 Aug 2024"},{"key":"1155_CR144","doi-asserted-by":"publisher","first-page":"2","DOI":"10.17925\/USN.2022.18.1.2","volume":"18","author":"T Wang","year":"2022","unstructured":"Wang T, Krauss GL. XEN1101: a novel potassium channel modulator for the Potential Treatment of Focal Epilepsy in adults. Touchrev Neurol. 2022;18:2\u20134. https:\/\/doi.org\/10.17925\/USN.2022.18.1.2.","journal-title":"Touchrev Neurol."},{"issue":"11","key":"1155_CR145","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/acn3.50896","volume":"6","author":"I Premoli","year":"2019","unstructured":"Premoli I, Rossini PG, Goldberg PY, Posadas K, Green L, Yogo N, Pimstone S, Abela E, Beatch GN, Richardson MP. TMS as a pharmacodynamic indicator of cortical activity of a novel anti-epileptic drug, XEN1101. Ann Clin Transl Neurol. 2019;6(11):2164\u201374. https:\/\/doi.org\/10.1002\/acn3.50896.","journal-title":"Ann Clin Transl Neurol"},{"key":"1155_CR146","doi-asserted-by":"publisher","unstructured":"French JA, Porter RJ, Perucca E, Brodie MJ, Rogawski MA, Pimstone S, Aycardi E, Harden C, Qian J, Rosenblut CL, Kenney C, Beatch GN, X-TOLE study group. Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: a phase 2b randomized clinical trial. JAMA Neurol. 2023;80(11):1145\u201354. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3542.","DOI":"10.1001\/jamaneurol.2023.3542"},{"key":"1155_CR147","doi-asserted-by":"crossref","unstructured":"Porter RJ, French J, Perucca E, Brodie M, Harden C, Rosenblut CL, Qian J, Kenney C, Beatch GN. The impact of disease severity on responder rate in a Phase 2b study of XEN1101, a potent, selective potassium channel opener, in adults with focal onset epilepsy (X-TOLE). Poster presented at the Annual Meeting of the American Academy of Neurology, April 13\u201318, 2024, Denver, CO. https:\/\/www.xenon-pharma.com\/wp-content\/uploads\/2024\/04\/AANOralPorter.pdf. Accessed 21 Sept 2024.","DOI":"10.1212\/WNL.0000000000205867"},{"key":"1155_CR148","doi-asserted-by":"crossref","unstructured":"French J, Porter R, Perucca E, Brodie M, Rogawski M, Harden C, Qian J, Rosenblut CL, Kenney C, Beatch GN. Interim long-term safety and efficacy of XEN1101, a potent, selective potassium channel opener: update from an ongoing, open-label extension of a phase 2b study (X-TOLE) in adults with focal epilepsy (poster 1.277). Presented at the American Epilepsy Society Annual Meeting; December 1\u20135, 2023; Orlando, FL. https:\/\/www.aesnet.org\/abstractslisting\/inter im-long-term-safety-and-efficacy-of-xen1101-a-potent-selective-potassium-channel-opener-update-from-an-ongoing-open-label-extension-of-a-phase-2b-study-x-tole-in- adults-with-focal-epilepsy. Accessed 22 Aug 2024.","DOI":"10.1212\/WNL.0000000000204537"},{"key":"1155_CR149","doi-asserted-by":"crossref","unstructured":"French J, Porter R, Perucca E, Brodie M, Rogawski M, Harden C, Qian J, Rosenblut CL, Kenney C, Beatch GN. Axetukalner (XEN1101), a novel, potent, Kv7 potassium channel opener: Interim data from an ongoing, long-term open-label extension of a phase 2b study (X- TOLE) in adults with focal onset seizures. Poster presented at the 15th European Epilepsy Congress, September 7\u201311, 2024, Rome, Italy. https:\/\/www.xenon-pharma.com\/wp-content\/uploads\/2024\/09\/EEC24French.pdfy. Accessed 22 Aug 2024.","DOI":"10.1212\/WNL.0000000000204537"},{"key":"1155_CR150","unstructured":"Picchione KE, Inglis AM, Resnick L, Mareska DA, Bozik ME, Dworetzky S. Discovery and Characterization of KB-3061: A potent Kv7.2\/7.3 ion channel activator for the treatment of KCNQ2-neonatal epileptic encephalopathy. Presented at the Annual Meeting of the American Epilepsy Society, Baltimore, MA, December 6\u201310, 2019 (abstract 3.045). https:\/\/aesnet.org\/abstractslisting\/discovery-and-characterization-of-kb-3061--a-potent-kv7- 2\/7-3-ion-channel-activator-for-the-treatment-of-kcnq2-neonatal-epileptic-encephalopathy. Accessed 27 Aug 2024."},{"key":"1155_CR151","doi-asserted-by":"crossref","unstructured":"Picchione K, Resnick L, Bozik M, Dworetzky S. Characterization of BHV-7000: a novel Kv7.2\/7.3 activator for the treatment of seizures. Presented at the American Epilepsy Society Annual Meeting. Orlando, FL, December 1-5, 2023. Poster 2.249. https:\/\/aesnet.org\/abstractslisting\/characterization-of-bhv-7000-a-novel-kv7-2-7-3-activator-for-the-treatment-of-seizures Accessed 27 Aug 2024.","DOI":"10.1212\/WNL.0000000000206250"},{"key":"1155_CR152","doi-asserted-by":"publisher","unstructured":"Picchione K, Resnick L, Bozik M, Dworetzky S. Characterization of BHV-7000: a novel Kv7.2\/7.3 activator for the treatment of seizures. Presented at the American Academy of Neurology Annual Meeting, Denver, CO, April 13-18, 2024. Neurology 102 (suppl 1). https:\/\/doi.org\/10.1212\/WNL.0000000000206250.","DOI":"10.1212\/WNL.0000000000206250"},{"key":"1155_CR153","unstructured":"Vanoye CG, Desai RR, Dworetzky S, George AL, Jr. HV-7000 Is a potent m-current activator with efficacy on multiple epilepsy-associated KCNQ2 variants. Presented at American Epilepsy Society Annual Meeting. December 6-10, 2024; Los Angeles, CA. https:\/\/aesnet.org\/abstractslisting\/bhv-7000-is-a-potent-m-current-activator-with-efficacy-on-multiple-epilepsy-associated-kcnq2-variants Accessed 18 Dec 2024."},{"key":"#cr-split#-1155_CR154.1","doi-asserted-by":"crossref","unstructured":"Lerner J, Awsare B, Sevinsky E, Ashbrenner E, Killingsworth R, Kendrick R, Vereycken E, Colenbier N, Neuray C, van Mierlo P, Slater J, Wyatt D, Qureshi I, Dworetzky S, Bozik M. Novel, selective Kv7.2\/7.3 potassium channel Activator, BHV-7000, demonstrates dose- dependent pharmacodynamic effects on eeg parameters in healthy adults. Presented at the American Epilepsy Society Annual Meeting. December 1-5, 2023","DOI":"10.1016\/j.neurot.2024.e00402"},{"key":"#cr-split#-1155_CR154.2","unstructured":"Orlando, FL. Poster 2.510. https:\/\/aesnet.org\/abstractslisting\/novel-selective-kv7-2-7-3-potassium-channel-activator-bhv-7000-demonstrates-dose-dependent-pharmacodynamic-effects-on-eeg-parameters-in-healthy- adults. Accessed 20 August 2024."},{"key":"1155_CR155","doi-asserted-by":"publisher","unstructured":"Lerner J, Awsare B, Sevinsky H, Ashbrenner E, Killingsworth R, Kendrick R, Vereycken E, Colenbrier N, Neuray C, van Mierlo P, Slater J, Wyatt D, Qureshi I, Dworetzky S, Bozik M. Novel, selective Kv7.2\/7.3 potassium channel Activator, BHV-7000, demonstrates dose- dependent pharmacodynamic effects on EEG parameters in healthy adults. Presented at the American Academy of Neurology Annual Meeting, Denver, CO, April 13-18, 2024 Academy of Neurology Annual Meeting, Denver, CO, April 13-18, 2024 Neurology 2024;102 (suppl 1). https:\/\/doi.org\/10.1212\/WNL.0000000000206367. Accessed 20 Aug 2024.","DOI":"10.1212\/WNL.0000000000206367"},{"key":"1155_CR156","doi-asserted-by":"crossref","unstructured":"Awsare B, Munivar A, Ashbrenner E, Sevinsky H, Bozik M, Dworetzky S, Donahue L, Killingsworth R, Francoeur B, Qureshi I. Safety and tolerability of BHV-7000, a novel Kv7 potassium channel activator: results from phase 1 single and multiple ascending dose Studies. Poster presented at the American Society of Clinical Psychopharmacology Annual Meeting, Miami Beach, FL, May 28\u201331, 2024. https:\/\/c6a2x5m8.rocketcdn.me\/wp-content\/uploads\/ASCP-2024-Poster-BHV-7000-SAD-MAD.pdf. Accessed 20 Aug 2024.","DOI":"10.1016\/j.neurot.2024.e00401"},{"key":"1155_CR157","doi-asserted-by":"publisher","unstructured":"Awsare B, Lerner J, Ashbrenner E, Sevinsky H, Bozik M, Dworetzky S, Donahue L, Killingsworth R, Francoeur B, Qureshi I. Phase 1 study evaluating the safety and tolerability of BHV-7000, a novel, selective Kv7.2\/7.3 potassium channel activator, in healthy adults. Presented at the American Academy of Neurology Annual Meeting, Denver, CO, April 13-18, 2024. Neurology 2024;102 (suppl 1). https:\/\/doi.org\/10.1212\/WNL.0000000000206409. Accessed 20 Aug 2024.","DOI":"10.1212\/WNL.0000000000206409"},{"key":"1155_CR158","doi-asserted-by":"publisher","unstructured":"Roeloffs R, Wickenden AD, Crean C, Werness S, McNaughton-Smith G, Stables J, McNamara JO, Ghodadra N, Rigdon GC. In vivo profile of ICA-27243 [N-(6-chloro-pyridin- 3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2\/Q3 (Kv7.2\/Kv7.3) activator in rodent anticonvulsant models. J Pharmacol Exp Ther. 2008;326(3):818\u201328. https:\/\/doi.org\/10.1124\/jpet.108.137794.","DOI":"10.1124\/jpet.108.137794"},{"issue":"2","key":"1155_CR159","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1021\/jm901497b","volume":"53","author":"PC Fritch","year":"2010","unstructured":"Fritch PC, McNaughton-Smith G, Amato GS, Burns JF, Eargle CW, Roeloffs R, Harrison W, Jones L, Wickenden AD. Novel KCNQ2\/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain. J Med Chem. 2010;53(2):887\u201396. https:\/\/doi.org\/10.1021\/jm901497b.","journal-title":"J Med Chem"},{"issue":"6","key":"1155_CR160","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1021\/ml200053x","volume":"2","author":"G Amato","year":"2011","unstructured":"Amato G, Roeloffs R, Rigdon GC, Antonio B, Mersch T, McNaughton-Smith G, Wickenden AD, Fritch P, Suto MJ. N-Pyridyl and pyrimidine benzamides as KCNQ2\/Q3 potassium channel openers for the treatment of epilepsy. ACS Med Chem Lett. 2011;2(6):481\u20134. https:\/\/doi.org\/10.1021\/ml200053x.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"1155_CR161","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.eplepsyres.2012.10.001","volume":"103","author":"M Bialer","year":"2013","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013;103(1):2\u201330. https:\/\/doi.org\/10.1016\/j.eplepsyres.2012.10.001.","journal-title":"Epilepsy Res"},{"issue":"8","key":"1155_CR162","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/epi.12224","volume":"54","author":"DG Kasteleijn-Nolst Trenit\u00e9","year":"2013","unstructured":"Kasteleijn-Nolst Trenit\u00e9 DG, Biton V, French JA, Abou-Khalil B, Rosenfeld WE, Diventura B, Moore EL, Hetherington SV, Rigdon GC. Kv7 potassium channel activation with ICA- 105665 reduces photoparoxysmal EEG responses in patients with epilepsy. Epilepsia. 2013;54(8):1437\u201343. https:\/\/doi.org\/10.1111\/epi.12224.","journal-title":"Epilepsia"},{"key":"1155_CR163","doi-asserted-by":"publisher","unstructured":"Aleo MD, Aubrecht J, D Bonin P, Burt DA, Colangelo J, Luo L, Schomaker S, Swiss R, Kirby S, C Rigdon G, Dua P. Phase I study of PF\u201004895162, a Kv7 channel opener, reveals unexpected hepatotoxicity in healthy subjects, but not rats or monkeys: clinical evidence of disrupted bile acid homeostasis. Pharmacol Res Perspect. 2019 ;7(1):e00467. https:\/\/doi.org\/10.1002\/prp2.467.","DOI":"10.1002\/prp2.467"},{"issue":"6","key":"1155_CR164","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.523","volume":"7","author":"G Generaux","year":"2019","unstructured":"Generaux G, Lakhani VV, Yang Y, Nadanaciva S, Qiu L, Riccardi K, Di L, Howell BA, Siler SQ, Watkins PB, Barton HA, Aleo MD, Shoda LKM. Quantitative systems toxicology (QST) reproduces species differences in PF-04895162 liver safety due to combined mitochondrial and bile acid toxicity. Pharmacol Res Perspect. 2019;7(6): e00523. https:\/\/doi.org\/10.1002\/prp2.523.","journal-title":"Pharmacol Res Perspect"},{"issue":"9","key":"1155_CR165","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.1021\/acs.jmedchem.0c02252","volume":"64","author":"YM Zhang","year":"2021","unstructured":"Zhang YM, Xu HY, Hu HN, Tian FY, Chen F, Liu HN, Zhan L, Pi XP, Liu J, Gao ZB, Nan FJ. Discovery of HN37 as a potent and chemically stable antiepileptic drug candidate. J Med Chem. 2021;64(9):5816\u201337. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c02252.","journal-title":"J Med Chem"},{"issue":"13","key":"1155_CR166","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.3390\/molecules28134888","volume":"28","author":"YJ Sun","year":"2023","unstructured":"Sun YJ, Gong YL, Lu SC, Zhang SP, Xu S. Three-step synthesis of the antiepileptic drug candidate pynegabine. Molecules. 2023;28(13):4888. https:\/\/doi.org\/10.3390\/molecules28134888.","journal-title":"Molecules"},{"key":"1155_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105860","volume":"174","author":"F Tian","year":"2022","unstructured":"Tian F, Cao B, Xu H, Zhan L, Nan F, Li N, Taglialatela M, Gao Z. Epilepsy phenotype and response to KCNQ openers in mice harboring the Kcnq2 R207W voltage-sensor mutation. Neurobiol Dis. 2022;174: 105860. https:\/\/doi.org\/10.1016\/j.nbd.2022.105860.","journal-title":"Neurobiol Dis"},{"issue":"9","key":"1155_CR168","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70002","volume":"30","author":"S Wei","year":"2024","unstructured":"Wei S, Shiwen W, Cao-Wenjing C, Huajun Y, Qun W. A randomized, double-blind, placebo- controlled, dose-escalating phase IIa trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of multiple oral doses of Pynegabine tablets as add-on therapy in patients with focal epilepsy. CNS Neurosci Ther. 2024;30(9): e70002. https:\/\/doi.org\/10.1111\/cns.70002.","journal-title":"CNS Neurosci Ther"},{"issue":"9","key":"1155_CR169","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41573-024-00981-w","volume":"23","author":"P Klein","year":"2024","unstructured":"Klein P, Kaminski RM, Koepp M, L\u00f6scher W. New epilepsy therapies in development. Nat Rev Drug Discov. 2024;23(9):682\u2013708. https:\/\/doi.org\/10.1038\/s41573-024-00981-w.","journal-title":"Nat Rev Drug Discov"},{"key":"1155_CR170","unstructured":"Adis International Ltd. CB 03. AdisInsight, updated 3 October 2024. https:\/\/adisinsight.springer.com\/drugs\/800057520. Accessed 20 Oct 2024."},{"key":"1155_CR171","unstructured":"Synapse (Patsnap). CB03. https:\/\/synapse.patsnap.com\/homepage\/search?query=eJyrVkpJLEmML6ksSFWyUkrMyVHSUSosTS2qVLKqVoKKphfllxYAxXNLi0uUrKLh4mmZqTkpQHEwXQyUUXL08Yl383T1 cQlWitVRKkvMKU1F1lCSWlGiBBdXcnYyMAZyUzKLC3ISK- PzEnNT41PzcEgkwyVqY4GwFgDMKDuc. Accessed 20 Oct 2024."},{"key":"1155_CR172","unstructured":"Biospace. Zhimeng Biopharma CB03 received orphan drug designation from the US FDA \u2013 A potassium ion channel opener for amyotrophic lateral sclerosis. October 20, 2023. https:\/\/www.biospace.com\/zhimeng-biopharma-cb03-received-orphan-drug-designation-from-the-us-fda-a-potassium-ion-channel-opener-for-amyotrophic-lateral-sclerosis. Accessed 20 Oct 2024."},{"issue":"6","key":"1155_CR173","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1517\/14728222.7.6.737","volume":"7","author":"VK Gribkoff","year":"2003","unstructured":"Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets. 2003;7(6):737\u201348. https:\/\/doi.org\/10.1517\/14728222.7.6.737.","journal-title":"Expert Opin Ther Targets"},{"key":"1155_CR174","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/164_2021_457","volume":"267","author":"F Jones","year":"2021","unstructured":"Jones F, Gamper N, Gao H. Kv7 Channels and excitability disorders. Handb Exp Pharmacol. 2021;267:185\u2013230. https:\/\/doi.org\/10.1007\/164_2021_457.","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"1155_CR175","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117350","volume":"10","author":"J Sval\u00f8","year":"2015","unstructured":"Sval\u00f8 J, Sheykhzade M, Nordling J, Matras C, Bouchelouche P. Functional and molecular evidence for Kv7 channel subtypes in human detrusor from patients with and without bladder outflow obstruction. PLoS ONE. 2015;10(2): e0117350. https:\/\/doi.org\/10.1371\/journal.pone.0117350.","journal-title":"PLoS ONE"},{"issue":"23","key":"1155_CR176","doi-asserted-by":"publisher","first-page":"8829","DOI":"10.1523\/JNEUROSCI.5176-14.2015","volume":"35","author":"BI Kalappa","year":"2015","unstructured":"Kalappa BI, Soh H, Duignan KM, Furuya T, Edwards S, Tzingounis AV, Tzounopoulos T. Potent KCNQ2\/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus. J Neurosci. 2015;35(23):8829\u201342. https:\/\/doi.org\/10.1523\/JNEUROSCI.5176-14.2015.","journal-title":"J Neurosci"},{"issue":"1","key":"1155_CR177","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/aps.2015.142","volume":"37","author":"JF Yue","year":"2016","unstructured":"Yue JF, Qiao GH, Liu N, Nan FJ, Gao ZB. Novel KCNQ2 channel activators discovered using fluorescence-based and automated patch-clamp-based high-throughput screening techniques. Acta Pharmacol Sin. 2016;37(1):105\u201310. https:\/\/doi.org\/10.1038\/aps.2015.142.","journal-title":"Acta Pharmacol Sin"},{"key":"1155_CR178","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1124\/mol.115.103200","volume":"89","author":"M Kumar","year":"2016","unstructured":"Kumar M, Reed N, Liu R, Aizenman E, Wipf P, Tzounopoulos T. Synthesis and evaluation of potent KCNQ2\/3-specific channel activators. Mol Pharmacol. 2016;89:667\u201377. https:\/\/doi.org\/10.1124\/mol.115.103200.","journal-title":"Mol Pharmacol"},{"key":"1155_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173440","volume":"887","author":"M Grupe","year":"2020","unstructured":"Grupe M, Bentzen BH, Benned-Jensen T, Nielsen V, Frederiksen K, Jensen HS, Jacobsen AM, Skibsbye L, Sams AG, Grunnet M, Rottl\u00e4nder M, Bastlund JF. In vitro and in vivo characterization of Lu AA41178: a novel, brain penetrant, pan-selective Kv7 potassium channel opener with efficacy in preclinical models of epileptic seizures and psychiatric disorders. Eur J Pharmacol. 2020;887: 173440. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173440.","journal-title":"Eur J Pharmacol"},{"key":"1155_CR180","unstructured":"Bastlund J, Larsen M. The pan-active kv7.2-5 activator, AA41178 is anticonvulsant and displays efficacy in animal models for psychiatric disorders. Presented at: American Epilepsy Society Annual Meeting; December 2\u20136, 2022, Nashville, TN. https:\/\/aesnet.org\/abstractslisting\/the-pan-active-kv7-2-5-activator--aa41178-is-anticonvulsant-and-display-efficacy-in-animal-models-for-psychiatric-disorders. Accessed 24 June 2024."},{"issue":"4","key":"1155_CR181","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/epi.17884","volume":"65","author":"SW Terman","year":"2024","unstructured":"Terman SW, Kirkpatrick L, Akiyama LF, Baajour W, Atilgan D, Dorotan MKC, Choi HW, French JA. Current state of the epilepsy drug and device pipeline. Epilepsia. 2024;65(4):833\u201345. https:\/\/doi.org\/10.1111\/epi.17884.","journal-title":"Epilepsia"},{"issue":"10","key":"1155_CR182","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1111\/epi.18092","volume":"65","author":"H Wang","year":"2024","unstructured":"Wang H, Qiao Z, Luan K, Xiang W, Chang X, Zhang Y, Wei N, Wang K. Identification of a new retigabine derivative with improved photostability for selective activation of neuronal Kv7 channels and antiseizure activity. Epilepsia. 2024;65(10):2923\u201334. https:\/\/doi.org\/10.1111\/epi.18092.","journal-title":"Epilepsia"},{"issue":"2","key":"1155_CR183","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/jpet.122.001328","volume":"384","author":"XF Zhuang","year":"2023","unstructured":"Zhuang XF, Liu YX, Yang ZH, Gao Q, Wang L, Ju C, Wang K. Attenuation of epileptogenesis and cognitive deficits by a selective and potent Kv7 channel opener in rodent models of seizures. J Pharmacol Exp Ther. 2023;384(2):315\u201325. https:\/\/doi.org\/10.1124\/jpet.122.001328.","journal-title":"J Pharmacol Exp Ther"},{"key":"1155_CR184","unstructured":"Protheragen Inc. Oral KCNQ2\/3 Potassium Channel Opener for Epilepsy Treatment. ZM-003. https:\/\/www.protheragen.com\/pdf-down\/oral-kcnq2-3-potassium-channel-opener-for-epilepsy-treatment trashed\/. Accessed 19 Oct 2024."},{"key":"1155_CR185","doi-asserted-by":"publisher","unstructured":"Ottosson NE, Silver\u00e5 Ejneby M, Wu X, Estrada-Mondrag\u00f3n A, Nilsson M, Karlsson U, Schupp M, Rognant S, Jepps TA, Konradsson P, Elinder F. Synthetic resin acid derivatives selectively open the hK(V) 7.2\/7.3 channel and prevent epileptic seizures. Epilepsia. 2021;62(7):1744\u201358. https:\/\/doi.org\/10.1111\/epi.16932.","DOI":"10.1111\/epi.16932"},{"key":"1155_CR186","doi-asserted-by":"publisher","unstructured":"Bock C, Surur AS, Beirow K, Kindermann MK, Schulig L, Bodtke A, Bednarski PJ, Link A. Sulfide analogues of flupirtine and retigabine with Nanomolar K(V) 7.2\/K(V) 7.3 channel opening activity. ChemMedChem. 2019;14(9):952\u201364. https:\/\/doi.org\/10.1002\/cmdc.201900112.","DOI":"10.1002\/cmdc.201900112"},{"key":"1155_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108884","volume":"203","author":"P Bloms-Funke","year":"2022","unstructured":"Bloms-Funke P, Bankstahl M, Bankstahl J, Kneip C, Schr\u00f6der W, L\u00f6scher W. The novel dual-mechanism Kv7 potassium channel\/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model. Neuropharmacology. 2022;203: 108884. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108884.","journal-title":"Neuropharmacology"},{"key":"1155_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.174935","volume":"923","author":"P Bloms-Funke","year":"2022","unstructured":"Bloms-Funke P, Schumacher M, Liu S, Su D, Li J, Liere P, Rupprecht R, Nothdurfter C, Bahrenberg G, Christoph T, Habermann C, Kneip C, Schr\u00f6der W, Tzschentke TM, Saunders D. A novel dual mode-of-action anti-hyperalgesic compound in rats which is neuroprotective and promotes neuroregeneration. Eur J Pharmacol. 2022;923: 174935. https:\/\/doi.org\/10.1016\/j.ejphar.2022.174935.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"1155_CR189","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00406-022-01532-3","volume":"273","author":"R Rupprecht","year":"2023","unstructured":"Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G. Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1477\u201387. https:\/\/doi.org\/10.1007\/s00406-022-01532-3.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1155_CR190","doi-asserted-by":"publisher","unstructured":"Raveh A, Pen Y, Silberman A, Peretz A, Attali B, Maile L, Davidson S, Brown AD, Kennedy JD, Belinson H. Dual Kv7.2\/3-TRPV1 modulators inhibit nociceptor hyperexcitability and alleviate pain without target-related side effects. Pain. 2024. https:\/\/doi.org\/10.1097\/j.pain.0000000000003390.","DOI":"10.1097\/j.pain.0000000000003390"},{"key":"1155_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2024.102634","volume":"240","author":"K Soca\u0142a","year":"2024","unstructured":"Soca\u0142a K, Jakubiec M, Abram M, Mlost J, Starowicz K, Kami\u0144ski RM, Ciepiela K, Andres-Mach M, Zagaja M, Metcalf CS, Zawadzki P, Wla\u017a P, Kami\u0144ski K. TRPV1 channel in the pathophysiology of epilepsy and its potential as a molecular target for the development of new antiseizure drug candidates. Prog Neurobiol. 2024;240: 102634. https:\/\/doi.org\/10.1016\/j.pneurobio.2024.102634.","journal-title":"Prog Neurobiol"},{"key":"1155_CR192","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/BF01676972","volume":"92","author":"J Bernstein","year":"1902","unstructured":"Bernstein J. Untersuchungen zur thermodynamik der bioelektrischen Str\u00f6me. Pfl\u00fcgers Arch. 1902;92:521\u201362. https:\/\/doi.org\/10.1007\/BF01676972.","journal-title":"Pfl\u00fcgers Arch"},{"issue":"1","key":"1155_CR193","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/35036198","volume":"1","author":"TJ Jentsch","year":"2000","unstructured":"Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci. 2000;1(1):21\u201330. https:\/\/doi.org\/10.1038\/35036198.","journal-title":"Nat Rev Neurosci"},{"issue":"5\u20136","key":"1155_CR194","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/17512433.2024.2337012","volume":"17","author":"S Lattanzi","year":"2024","unstructured":"Lattanzi S, Trinka E, Meletti S, Striano P, Matricardi S, Silvestrini M, Brigo F. A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy. Expert Rev Clin Pharmacol. 2024;17(5\u20136):423\u201332. https:\/\/doi.org\/10.1080\/17512433.2024.2337012.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"1155_CR195","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1212\/CPJ.0000000000000874","volume":"11","author":"M Mula","year":"2021","unstructured":"Mula M, Kanner AM, Jett\u00e9 N, Sander JW. Psychiatric comorbidities in people with epilepsy. Neurol Clin Pract. 2021;11(2):e112\u201320. https:\/\/doi.org\/10.1212\/CPJ.0000000000000874.","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"1155_CR196","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/nau.22920","volume":"36","author":"N Aizawa","year":"2017","unstructured":"Aizawa N, Wakamatsu D, Kida J, Otsuki T, Saito Y, Matsuya H, Homma Y, Igawa Y. Inhibitory effects of retigabine, a Kv7 channel activator, on mechanosensitive primary bladder afferent activities and nociceptive behaviors in rats. Neurourol Urodyn. 2017;36(2):280\u20135. https:\/\/doi.org\/10.1002\/nau.22920.","journal-title":"Neurourol Urodyn"},{"issue":"23\u201324","key":"1155_CR197","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1016\/j.bmcl.2018.09.036","volume":"28","author":"MA Seefeld","year":"2018","unstructured":"Seefeld MA, Lin H, Holenz J, Downie D, Donovan B, Fu T, Pasikanti K, Zhen W, Cato M, Chaudhary KW, Brady P, Bakshi T, Morrow D, Rajagopal S, Samanta SK, Madhyastha N, Kuppusamy BM, Dougherty RW, Bhamidipati R, Mohd Z, Higgins GA, Chapman M, Rouget C, Lluel P, Matsuoka Y. Novel KV7 ion channel openers for the treatment of epilepsy and implications for detrusor tissue contraction. Bioorg Med Chem Lett. 2018;28(23\u201324):3793\u20137. https:\/\/doi.org\/10.1016\/j.bmcl.2018.09.036.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"1155_CR198","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00210-016-1312-9","volume":"390","author":"R Bientinesi","year":"2017","unstructured":"Bientinesi R, Mancuso C, Martire M, Bassi PF, Sacco E, Curr\u00f2 D. K(V)7 channels in the human detrusor: channel modulator effects and gene and protein expression. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(2):127\u201337. https:\/\/doi.org\/10.1007\/s00210-016-1312-9.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"1155_CR199","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1113\/JP272762","volume":"595","author":"AW Wang","year":"2017","unstructured":"Wang AW, Yang R, Kurata HT. Sequence determinants of subtype-specific actions of KCNQ channel openers. J Physiol. 2017;595(3):663\u201376. https:\/\/doi.org\/10.1113\/JP272762.","journal-title":"J Physiol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01155-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01155-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01155-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:58:04Z","timestamp":1740412684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01155-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":200,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01155-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"22 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. The preparation of this article was not supported by any funding source.\u00a0The open access fee for this article was covered by The University of Melbourne.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"EP received speaker fees or fees from consulting or participation in Advisory Boards\/Data Safety Monitoring Board from Eisai, GRIN Therapeutics, SKL Life Science, Sintetica, Sun Pharma, Takeda, and Xenon Pharma, and royalties from Wiley, Elsevier, and Wolters Kluwers, all outside the submitted work. EP is an Editorial Board member of CNS Drugs. EP was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.\u00a0MT received consultancy fees from Xenon Pharmaceuticals, Angelini Pharma, Clexio Bioscience. MT is the inventor of new Kv7 activators, as described in two patents entitled \u201cPotassium channel activators and their use in treating disorders involving hyperexcitability\u201d (EP23220110.3), and \u201cNew modulators of Kv7 potassium channels, methods of preparation and therapeutical uses\u201d (PCT\/EP2019\/052067).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This article is an invited review. All authors contributed to the literature search. MT drafted the initial version of sections 1 and 2, and prepared Fig.  (with the help of Dr. Camilla Celentano, PhD student in Neuroscience at the University of Naples Federico II, Naples, Italy). EP prepared the initial draft of Sects. 3 and 4. Both authors participated equally in the finalization of the manuscript and met ICMJE criteria for authorship. Both authors have read and approved the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}